Literature DB >> 31631731

Pigmented paravenous chorioretinal atrophy revealing a chronic granulomatous disease.

Vasily M Smirnov1,2, Delphine Ley2,3, Brigitte Nelken2,4, Florence Petit2,5, Sabine Defoort-Dhellemmes1.   

Abstract

Background: Pigmented Paravenous Chorioretinal Atrophy (PPCRA) is a rare and predominantly sporadic form of chorioretinal atrophy. Ocular and systemic inflammation has been considered a possible etiology of PPCRA. In this report, we describe an unusual case of PPCRA in a child who was recently diagnosed with chronic granulomatous disease.Case description: A 4-year-old boy was referred for ophthalmic assessment after a seizure. Fundus examination revealed atrophic chorioretinal lesions typical of PPCRA. We had also referred this patient to a gastroenterologist for chronic abdominal pain and diarrhea. The patient was first diagnosed as a case of Crohn's disease, but in the setting of mesenteric lymphadenopathy, a workup for immune dysfunction was performed. Nitro-blue tetrazolium test (NBT) was negative, suggesting a chronic granulomatous disease, which was finally confirmed by genetic testing.
Conclusion: The presentation of PPCRA has been sporadic in the majority of cases. Inflammatory and hereditary origins have been anecdotally cited. Our young patient showed concurrent presentation of inflammatory and hereditary origin of PPCRA. We suggest that a careful investigation of systemic inflammation should be done in children with suggestive extraocular symptoms in the setting of PPCRA.

Entities:  

Keywords:  Pigmented paravenous chorioretinal atrophy; chronic granulomatous disease; pediatric retina

Mesh:

Year:  2019        PMID: 31631731     DOI: 10.1080/13816810.2019.1681009

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  1 in total

1.  Pigmented Paravenous Retinochoroidal Atrophy: A Case Report Supported by Multimodal Imaging Studies.

Authors:  Ilyoung Jung; Yeojin Lee; Seungbum Kang; Jaeyon Won
Journal:  Medicina (Kaunas)       Date:  2021-12-19       Impact factor: 2.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.